Thinning of the inner layers of the retina occurs in patients with central retinal artery occlusion (CRAO). The mechanism for such thinning may be partially due to proteolysis by a calcium-activated protease called calpain. Calpain inhibitor SNJ-1945 ameliorated the proteolysis in a past series of model experiments. The purposes of the present retrospective study were to: 1) use segmentation analysis of optical coherence tomography (OCT) images to mathematically model the loss of specific retinal layers in CRAO patients, and 2) predict the number of patients and days of observation needed for clinical trials of SNJ-1945 inhibitor against CRAO.
Treatments include: manual ocular massage, reduction of intraocular pressure (e.g., IV mannitol), vasodilation (paper bag or carbogen inhalation), and thrombolytic therapy (tissue plasminogen activator) (4). However, there is no consensus on treatment, and the final visual acuity of 90% of non-arteritic CRAO patients without cilioretinal artery sparing is 20/400 or worse (5) .
Our hypothesis is that at least part of the cellular damage to the RNFL and GCL in CRAO is due to activation of the calpain system of calcium-dependent proteases (6, 7) . A calpain inhibitor, SNJ-1945, ameliorated changes in the RNFL and GCL due to hypoxia in monkey retinal transplants. This inhibitor can be administered orally and is currently undergoing human safety trials. Thus, the purposes of the present experiments were: 1) to use segmentation analysis of OCT images to mathematically describe the loss of retinal layers in CRAO patients, and 2) predict the number of patients and days of observation needed for a clinical trial of SNJ-1945 against CRAO.
Materials and Methods
Using OHSU IRB protocol # 15821, a retrospective, case control study was conducted by computer-aided search in a medical records database for CRAO (ICD10 Therefore, the reference value for goodness fit, R2 (coefficient of determination), was considered biologically significant only if > 0.4. Cohen-d effect sizes were calculated as:
(Thickness no drug -Thickness drug )/root mean squared error of variance (RMSE)
Minimum patient numbers required per group were determined by using the Cohen-d effect size in a two tailed t-test with power of 0.8 and = 0.05 (9) 
Results
Demographics.
CRAO data were obtained from 19 patients with an average age at onset of 61.2 16.5 years (range 31-82); 63 % were male, and 89 % were non-Hispanic white patients ( Table 1) Fig. 3B ) and the entire RETINA (R2 = 0.71, Fig. 3A ). The fit for RNFL was only R2 = 0.38 (Fig. 3C ). The INL (Fig. 3F) showed an R2 = 0.32 with wide scatter, possibly due to the fact that it receives a secondary blood supply along with the central retinal artery. The outer layers ( Fig. 3G-K) were not well correlated and not further analyzed.
Patient sample size and duration of clinical trial
The specific regression formulas for each inner layer shown in each panel of Fig. 3 were used to calculate layer thickness at potential clinical trial end points of 30, 60, 90 120 and 180 days ( 
Discussion
GCL thickness as a marker for following CRAO. A conclusion of the studies above was that measurement of GCL thickness would be a useful indicator of CRAO progression in a clinical trial of calpain inhibitor. Data supporting this conclusion include: 1) Previous investigators found OCT measurements in specific layers of the macula to be useful for following the progression of CRAO (12) , as well as in other ocular diseases affecting the macula including age-related macular degeneration, diabetic retinopathy, retinal venous occlusion, and even glaucoma (11, 13) .
2) The fit (R2 = 0.75) for negative exponential decay for GCL during the acute and chronic phases of our CRAO cases was good (Fig. 3A) . A somewhat similar loss of total thickness in the perimacular region versus days was observed, which was described as linear in the chronic phase (14) . A more recent study (15) of 134 CRAO eyes found that 78 % showed macular edema at initial baseline, and that 99 % showed retinal thinning at final examination. 3) Poor definition of the RNFL and GCL in the peri/para macular region was noted previously (16) . Normal RNFL is especially thin (~ 23 um) near the fovea, possibly causing greater error when measuring the thinner RNFL in our studies. 4) Thickness measurements for 11 layers and zones in eyes not affected by CRAO eyes (Fig. 1) Using SNJ-1945 in such a human trial would further test our hypothesis that at least part of the inner layer thinning in CRAO is due calpain-induced proteolysis (6, 17) .
This is based on a series of observations over the last 20 years. For example, the calpain system is present in nearly all animal tissues (7), including non-human primate (6) and human (18) showed calpain specific breakdown products in the RNFL followed by TUNEL-staining later in the GCL layer. Importantly, SNJ-1945 ameliorated these changes. In cultured human retinas, hypoxia caused calpain activation and proteolysis; changes that were also ameliorated by SNJ-1945 (18) . The mechanism suggested by these observations for CRAO is that occlusion causes ischemia in the RNFL, energy production by the mitochondria decreases, calcium export from the RNFL is compromised, increased intracellular calcium activates calpains, proteins such asspectrin in the axonal RNFL are broken down by calpains, and calpain also degrades its natural inhibitor (calpastatin). Pro-apoptotic signal activation in the axons results in apoptotic thinning of the GCL. Although less specific for this calpain/SNJ-1945 hypothesis, our data in Table 1 showed total retina thickness and composite inner layer thickness measurements could also be used as surrogate markers for CRAO.
Limitations. Patients were excluded if the segmentation errors were detected. But since only a limited number of patients with OCT scans were available, patients in this study showed a wide age range and number of OCT scans; and many comorbidity factors, concomitant drug and treatment plans, and numerous surgeries and diseases were present. This increased the variability of the data, but represents the practical realities likely to be encountered in finding adequate CRAO patients.
Another consideration not addressed in the present study was visual acuity. 13 of the 19 patients in the present study showed marked vision loss at CF or worse. 
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